What’s new

• Blue Jet is shelving the ₹1,000 cr Vizag capex; FY26 spend will target de-bottlenecking and environmental infra.
• CDMO pipeline has contracted from 20 active RFPs to 4-5 key projects.
• Q2 revenue of ₹161 cr was hit by ₹20-25 cr logistical delays now resolved.

Why it matters

The dual shift, abandoning a flagship expansion and revealing a thinner deal funnel, rewrites the growth narrative for a company that was scaling toward large-scale contract manufacturing. H1 margins held at 34.4%, but the capital allocation pivot signals a more cautious posture.

What we’re watching

• Whether the pharma intermediate entering commercial production in 12 months fills the CDMO pipeline gap.
• How Unit 2 capacity ramp affects Contrast Media margins in H2.
• Any revised capex guidance beyond de-bottlenecking for FY27.

The full read

Blue Jet Healthcare just rewrote its capex playbook. The ₹1,000 crore Vizag expansion, a centrepiece of prior guidance, is off the table for now. In its place, FY26 spending will focus on de-bottlenecking and environmental infrastructure. That alone would have been the story. But the CDMO pipeline, which the company last discussed as 20 active RFPs, has narrowed to 4-5 key projects. One pharma intermediate is on track for commercial production within 12 months, but the headline shrinkage in the funnel is harder to ignore. Operationally, the quarter was mixed. Q2 revenue touched ₹161 crore, dragged down by ₹20-25 crore in logistical delays that have since been cleared. H1 EBITDA margin held at 34.4%, and the company posted ₹72 crore in net profit for the half-year. Contrast Media margins are expected to sit at 33-35% in H2 as Unit 2 capacity ramps. The financials hold. The growth thesis just got smaller.

Primary source: BSE · NSE